These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27230769)

  • 1. Brain regions associated with telomerase reverse transcriptase promoter mutations in primary glioblastomas.
    Fan X; Wang Y; Liu Y; Liu X; Zhang C; Wang L; Li S; Ma J; Jiang T
    J Neurooncol; 2016 Jul; 128(3):455-62. PubMed ID: 27230769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI Features Associated with TERT Promoter Mutation Status in Glioblastoma.
    Ivanidze J; Lum M; Pisapia D; Magge R; Ramakrishna R; Kovanlikaya I; Fine HA; Chiang GC
    J Neuroimaging; 2019 May; 29(3):357-363. PubMed ID: 30644143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deep Learning Radiomics for the Assessment of Telomerase Reverse Transcriptase Promoter Mutation Status in Patients With Glioblastoma Using Multiparametric MRI.
    Zhang H; Zhang H; Zhang Y; Zhou B; Wu L; Lei Y; Huang B
    J Magn Reson Imaging; 2023 Nov; 58(5):1441-1451. PubMed ID: 36896953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
    Yamashita K; Hatae R; Hiwatashi A; Togao O; Kikuchi K; Momosaka D; Yamashita Y; Kuga D; Hata N; Yoshimoto K; Suzuki SO; Iwaki T; Iihara K; Honda H
    Diagn Interv Imaging; 2019; 100(7-8):411-419. PubMed ID: 30948344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
    Matsumura N; Nakajima N; Yamazaki T; Nagano T; Kagoshima K; Nobusawa S; Ikota H; Yokoo H
    Neuropathology; 2017 Feb; 37(1):58-63. PubMed ID: 27302309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter mutations in primary and secondary glioblastomas.
    Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
    Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma.
    Ersoy TF; Keil VC; Hadizadeh DR; Gielen GH; Fimmers R; Waha A; Heidenreich B; Kumar R; Schild HH; Simon M
    Neuroradiology; 2017 Dec; 59(12):1223-1231. PubMed ID: 28894890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase reverse transcriptase promoter mutation- and O
    Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G
    Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
    Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
    Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A radiomics-based nomogram may be useful for predicting telomerase reverse transcriptase promoter mutation status in adult glioblastoma.
    Li Y; Chen L; Huang L; Li X; Huang Q; Tang L; Huang Z; Zhu L; Li T
    Brain Behav; 2024 May; 14(5):e3528. PubMed ID: 38798094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
    Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
    Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.
    Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH
    Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insular primary glioblastomas with IDH mutations: Clinical and biological specificities.
    Hata N; Hatae R; Yoshimoto K; Murata H; Kuga D; Akagi Y; Sangatsuda Y; Suzuki SO; Iwaki T; Mizoguchi M; Iihara K
    Neuropathology; 2017 Jun; 37(3):200-206. PubMed ID: 28116838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Extensive Surgical Resection of Butterfly Glioblastomas on Outcomes in the Presence of TERT Mutation and EGFR Amplification: A Retrospective Cohort Study.
    Hekimoglu M; Basak AT; Akgun MY; Ozer H; Ozgen U; Maleki R; Saban D; Oktenoğlu T; Ozer AF; Sasani M
    Cancer Control; 2024; 31():10732748241288121. PubMed ID: 39327682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparametric MRI-based fusion radiomics for predicting telomerase reverse transcriptase (TERT) promoter mutations and progression-free survival in glioblastoma: a multicentre study.
    Zhang H; Zhang H; Zhang Y; Zhou B; Wu L; Yang W; Lei Y; Huang B
    Neuroradiology; 2024 Jan; 66(1):81-92. PubMed ID: 37978079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.
    Diplas BH; He X; Brosnan-Cashman JA; Liu H; Chen LH; Wang Z; Moure CJ; Killela PJ; Loriaux DB; Lipp ES; Greer PK; Yang R; Rizzo AJ; Rodriguez FJ; Friedman AH; Friedman HS; Wang S; He Y; McLendon RE; Bigner DD; Jiao Y; Waitkus MS; Meeker AK; Yan H
    Nat Commun; 2018 May; 9(1):2087. PubMed ID: 29802247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations.
    Shibahara I; Sonoda Y; Suzuki H; Mayama A; Kanamori M; Saito R; Suzuki Y; Mashiyama S; Uenohara H; Watanabe M; Kumabe T; Tominaga T
    Brain Tumor Pathol; 2018 Jan; 35(1):10-18. PubMed ID: 29138945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
    Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
    Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR.
    Miki S; Satomi K; Ohno M; Matsushita Y; Kitahara M; Miyakita Y; Takahashi M; Matsuda M; Ishikawa E; Matsumura A; Yoshida A; Narita Y; Ichimura K
    Brain Tumor Pathol; 2020 Oct; 37(4):154-158. PubMed ID: 32749624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.